<DOC>
	<DOCNO>NCT00251446</DOCNO>
	<brief_summary>This Phase II , single-arm study patient stage IIIB ( malignant pleural effusion ) IV NSCLC previously treat platinum-based doublet . Each cycle 21 day . On Day 1 cycle , patient receive vinflunine 320 mg/m2 20-minute IV infusion . Patients continue receive study treatment disease progression unacceptable toxicity . Patients evaluate every 2 cycle response use RECIST criterion .</brief_summary>
	<brief_title>A Phase II Single Arm Trial Single-agent Vinflunine Second-line Treatment Advanced Non-Small Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Vinblastine</mesh_term>
	<criteria>To eligible study , patient must fulfill follow criterion : Patients must sign IRBapproved informed consent . Patients must recurrent metastatic stage IIIB ( malignant pleural effusion ) IV NSCLC progress receive platinumbased doublet firstline therapy . Patients must measurable disease , define Response Evaluation Criteria Solid Tumors ( RECIST ) criterion . Previously irradiated lesion allow measurable disease . Patients must ECOG Performance Status 0 , 1 , 2 . Patients must &lt; 18 year age . Previous chemotherapy must complete least 4 week prior enrollment . Patients must either child bear potential negative serum pregnancy test within 7 day prior registration . Patients consider child bear potential surgically sterile ( undergone hysterectomy , bilateral tubal ligation bilateral oophorectomy ) postmenopausal least 12 month . Patients childbearing potential must agree use effective contraceptive measure study treatment reasonable time thereafter . Patients must absolute neutrophil count ( ANC ) &gt; 1500/uL , platelet count &gt; 100,000/uL , hemoglobin &gt; 8 g/dL . Patients must serum creatinine &lt; 2 x institutional upper limit normal ( ULN ) . Patients must total bilirubin &lt; 2.5 x ULN aspartate transaminase ( AST ) &lt; 5.0 x ULN . Any follow criterion make patient ineligible participate study : Patients previously treat vinflunine another vinca alkaloid . Patients untreated clinically unstable brain metastasis . Significant history uncontrolled cardiac disease ; i.e. , uncontrolled hypertension , unstable angina , recent myocardial infarction ( within prior 6 month ) , uncontrolled congestive heart failure , cardiomyopathy decrease ejection fraction . Patients serious uncontrolled intercurrent medical psychiatric illness , include serious infection . Patient coexist malignancy malignancy diagnose within last 3 year , exception basal cell carcinoma cervical cancer situ . Patient receive treatment nonapproved investigational drug within 30 day plan start study treatment . Patient completely heal previous oncologic major surgery . Patient receive plan receive concurrent chemotherapy indicate study protocol investigational agent study period . Patients history hypersensitivity vinflunine component vinflunine another vinca alkaloid . Any patient pregnant lactating . Any patient unable comply requirement study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2012</verification_date>
</DOC>